Anti-Hypertensive Drugs - Nordics

Nordics

In the Nordics, the revenue in the Anti-Hypertensive Drugs market is projected to reach US$264.60m in 2024.
Looking ahead, it is expected that the revenue will experience an annual growth rate (CAGR 2024-2029) of -0.41%, leading to a market volume of US$259.20m by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in this market, with an estimated value of US$12,290.00m in 2024.
The Nordic countries have seen a growing demand for innovative anti-hypertensive drugs, driven by their strong focus on healthcare and high prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Nordics region has been witnessing a significant growth in the Anti-Hypertensive Drugs market in recent years.

Customer preferences: The customers in the Nordics region are becoming increasingly health-conscious, which is driving the demand for Anti-Hypertensive Drugs. The aging population and the high prevalence of hypertension are also contributing to the growth of the market.

Trends in the market: The market is witnessing a shift towards combination therapies, which offer better efficacy and convenience to the patients. The introduction of fixed-dose combinations is also driving the growth of the market. The market is dominated by branded drugs, but the entry of generic drugs is expected to increase competition and reduce prices.

Local special circumstances: The Nordics region has a well-developed healthcare system, which provides universal access to healthcare services. The governments in the region are also promoting the use of generic drugs to reduce healthcare costs. The region has a strong pharmaceutical industry, which is investing in the development of new drugs and therapies.

Underlying macroeconomic factors: The Nordics region has a strong economy and a high standard of living, which enables the population to afford expensive drugs. The region also has a high level of healthcare expenditure, which is driving the growth of the market. The governments in the region are also investing in healthcare infrastructure and research and development, which is expected to boost the growth of the market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.